Price To Earnings Ratio 51.56 | Sector PE 66.94 |
PB Ratio 6.96 | Sector PB 8.53 |
EPS 42.01 | Dividend Yield 0.49 |
Today's Volume 185.765 K | 5 Day Avg. Volume 527.027 K |
PEG Ratio 0.15 | Market Cap. ₹ 94,970.00 Cr. |
Lupin Limited is an Indian pharmaceutical company. The company manufactures, develops and markets a variety of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) worldwide. The company operates in the Cardiovascular, Diabetes, Asthma, Pediatric, CNS, Gastrointestinal, Anti-Infective and Non-Steroidal Anti-Inflammatory drug therapeutic segments and operates in the Anti-Tuberculosis and Cephalosporin segments. The company and its subsidiaries have manufacturing facilities in India, the United States, Mexico and Brazil, and trading and other ancillary and related activities also extend to global markets. Its complex generic portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol, among others. Its biosimilars include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim), and Etanercept.